2-氨基-2-脱氧-4-O-beta-D-吡喃半乳糖基-D-葡萄糖 | 13000-25-4

• 物质功能分类: 生物化工 - 糖类化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-氨基-2-脱氧-4-O-beta-D-吡喃半乳糖基-D-葡萄糖
• 中文别名: 4-O-(B-D吡喃半乳糖基)-D-葡糖胺
• 英文名称: (2R,3R,4S,5R)-2-amino-3,5,6-trihydroxy-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal
• CAS: 13000-25-4
• 化学式: C₁₂H₂₃NO₁₀
• 分子量: 341.31
• InChiKey: LAVNEPYDFKGEOD-JVCRWLNRSA-N

物化性质

• 熔点：
  >95°C (dec)
• 沸点：
  767.2±60.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于酸性水溶液（轻微，超声处理），甲醇（轻微）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -5.3
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  203
• 氢给体数：
  8
• 氢受体数：
  11

文献信息

• [EN] GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY<br/>[FR] FORMULATIONS DE GEL POUR AMÉLIORER L'EFFET DE RADIOTHÉRAPIE
  申请人：UNIV DENMARK TECH DTU

  公开号：WO2016079331A1

  公开（公告）日：2016-05-26

  The present invention relates to a composition comprising: a. non-water soluble carbohydrates b. a contrast agent for imaging, wherein at least 60% of the contrast agent remains within 10 cm from the injection site after 24h, for use in local co-administration into a human or animal body, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration.

  本发明涉及一种包含以下成分的组成物：a. 非水溶性碳水化合物 b. 成像的对比剂，其中至少60%的对比剂在24小时后保持在注射部位10厘米范围内，用于在人体或动物体内局部共同给药，并且该组成物在给药前为液态，在给药后在粘度上增加超过1,000厘泊（cP）。
• [EN] GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] INHIBITEUR GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2020078808A1

  公开（公告）日：2020-04-23

  The present invention relates to a compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及一种具有一般式I或II的化合物。式I或II的化合物适用于用于治疗与在哺乳动物（如人类）中的一个半乳糖结合蛋白（例如半乳糖结合蛋白-3）与配体结合有关的疾病的方法。此外，本发明涉及一种治疗与在哺乳动物（如人类）中的一个半乳糖结合蛋白（例如半乳糖结合蛋白-3）与配体结合有关的疾病的方法。
• [EN] HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES<br/>[FR] ANTICORPS ANTI-TN-MUC1 HUMANISÉS ET LEURS CONJUGUÉS
  申请人：CANCER REC TECH LTD

  公开号：WO2015159076A1

  公开（公告）日：2015-10-22

  Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.

  人性化抗Tn-MUC1抗体及其结合物。描述了包含吡咯苯并二氮杂环己烷（PBDs）的结合物，其具有作为连接物的不稳定保护基团。
• SUGAR CHAIN-ATTACHED LINKER, COMPOUND CONTAINING SUGAR CHAIN-ATTACHED LINKER AND PHYSIOLOGICALLY ACTIVE SUBSTANCE OR SALT THEREOF, AND METHOD FOR PRODUCING SAME
  申请人：GLYTECH INC.

  公开号：US20150306235A1

  公开（公告）日：2015-10-29

  To provide a carrier linker that is capable of improving the water solubility of a physiologically active substance and more quickly releasing the physiologically active substance under specific conditions without utilizing light or enzymatic cleavage. [Solution]A novel sugar chain-attached linker comprising a sugar chain that is attached as a carrier.

  提供一种载体连接剂，能够提高生理活性物质的水溶性，并在特定条件下更快地释放生理活性物质，而无需利用光或酶解。【解决方案】一种新型的糖链连接剂，包括作为载体附着的糖链。
• [EN] ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS<br/>[FR] INHIBITEURS ALPHA-D-GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2016120403A1

  公开（公告）日：2016-08-04

  The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns compounds for use in a method of treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及一般式（1）的化合物。其中吡喃糖环为α-D-半乳糖，A选自。该式（1）化合物适用于治疗与在哺乳动物，如人类中的一个配体结合相关的疾病的方法。此外，本发明涉及用于治疗与在哺乳动物，如人类中的一个配体结合相关的疾病的方法的化合物。